About Us

Our team of world-class scientists and biotechnology leadership is devoted to discovering breakthrough medicines that change the standard of medical care for patients.


Sir Martin Evans, Nobel Laureate, and Ajan Reginald, former Global Head of Emerging Technologies at Roche, originally founded the company under the name Cell Therapy Ltd (CTL) in 2009. CTL was rebranded as Celixir in 2016.

The potential of the use of stem cells within regenerative...
An entire replacement skin has been grown for the first...
Stem cell research has been able to achieve some incredible...
The use of stem cells has revolutionalised medicine over the...
Singapore | 16 November 2017

“Celixir's Phase IIb/ Phase III Regenerative Medicine Clinical Trials.”

Organized by World High Technology Society (WHTS), The 11th Annual World Congress of Regenerative Medicine & Stem Cell-2017 was held successfully at Holiday Inn Singapore Atrium during November 14-16, 2017. Read more about the event here.
Singapore 16-11-2017
“The differences in culture of institutional biotech investors in Europe versus the US, and how that impacts the ability of individual biotechs to grow and commercialise.”
London 10-05-2017
“Introduction to cell & gene therapy” and “Topic Based Partnering” Event details here
Germany 17-04-2017
Our Work in Pipeline
PHASE 2 : Our first investigational cardiac regenerative medicine consists...
PHASE 3 : Our investigational topical gel containing platelet lysate is...
CLINICAL TRIAL READY : PML cells are being investigated as...
Find Out More
Our pivotal position in the rapidly evolving regenerative medicine field is supported by a group of leading investors.
Our continued focus on innovation is the key to unlocking the potential of regenerative medicine. We combine the unique expertise of scientists
We are passionate about advancing ground-breaking regenerative medicines and work towards this goal via collaborative partnerships.
Twitter Feed